A phase I/II study of ZD1839 (Iressa) [gefitinib] given concurrently with radiotherapy in patients with non-metastatic prostate cancer.
Phase of Trial: Phase I/II
Latest Information Update: 12 May 2009
At a glance
- Drugs Gefitinib (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 12 May 2009 Actual patient number (42) added as reported by ClinicalTrials.gov.
- 12 May 2009 Actual end date changed from Nov 2004 to May 2006 as reported by ClinicalTrials.gov.